Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / GNFTF - Genfit: Iqirvo's Success Can't Outweigh ACLF Pipeline Risks

GNFTF - Genfit: Iqirvo's Success Can't Outweigh ACLF Pipeline Risks

Genfit

2025-05-12 13:19:58 ET

Summary

  • Genfit's Iqirvo, approved for PBC, generated $26M in Q1 2025, but faces competition from Gilead’s Livdelzi, limiting its market potential.
  • Genfit's focus is now on developing drugs for ACLF, a high-risk area with no approved treatments, making it a speculative investment.
  • Given the high risks and speculative nature of Genfit's ACLF pipeline, I rate GNFT as a Hold, suitable for a barbell portfolio.

Introduction

For further details see:

Genfit: Iqirvo's Success Can't Outweigh ACLF Pipeline Risks

Stock Information
Company Name: Genfit
Stock Symbol: GNFTF
Market: OTC
Website: genfit.com
Menu
GNFTF GNFTF Quote GNFTF Short GNFTF News GNFTF Articles GNFTF Message Board
Get GNFTF Alerts

News, Short Squeeze, Breakout and More Instantly...